Pharmacologic Class | First to be Marketed in the U.S. | FDA Approved Indication | |
C1 inhibitor | C1 inhibitor(CinryzeR) | Routine prophylaxis against angioedema attacks in patients with hereditary angioedema | |
CXCR4 chemokine receptor inhibitor | plerixa (MozobilR) | Mobilization of granulocyte-colony stimulating factor induced hematopoietic stem cells to the peripheral blood prior to collection | |
peripherally acting μ-opioid receptor antagonist | alvimopan (EnteregR) | Acceleration of the time to gastrointestinal recovery following bowel surgery | |
methylnaltrexone (RelistorR) | Treatment of opioid-induced constipation | ||
thrombopoietin receptor agonist | eltrombopag (PromactaR) | Treatment of thrombocytopenia in patients with chronic immune thrombocytopenic purpura |
Wednesday, April 1, 2009
Table: New Pharmacological Drug Classes Introduced in 2008
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Please add your comments or suggestions here..
Note: Only a member of this blog may post a comment.